MTAP and renal cell carcinoma: Based on the above results showing that a lack of MTAP contributes to RCC aggressiveness and activation of IGF1R signaling and in view of the critical roles of IGF1R in RCC oncogenesis,6 we attempted to test whether inhibition of IGF1R activity by linsitinib treatment impairs oncogenic phenotypes in MTAP-deficient cells.